Drugs News and Research

RSS

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

Allergan, Inc. today filed a declaratory relief action in the United States District Court for the District of Columbia seeking a ruling that would allow Allergan to proactively share truthful and relevant information with the medical community to assist physicians in evaluating the risks and benefits of BOTOX (onabotulinumtoxinA) for certain “off-label” therapeutic uses.

5 Oct 2009

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and the Japanese Cancer Association (JCA) presented 'The JCA-Mauvernay Award' to Dr Toshikazu Ushijima from the National Cancer Center Research Institute in Tokyo, for his outstanding and innovative research in basic science in the "epigenetic field for cancerization".

5 Oct 2009

CIGNA survey shows employees in small business look for ways to save money on medication

A recent CIGNA survey of consumers across the country found that employees at small companies are more likely than those employed by larger companies to look for ways to save money on prescription drugs. The same study found that 60 percent of consumers are willing to spend 30 minutes on a Web site comparing costs and services if it will save them $100.

5 Oct 2009

National experts to address epilepsy disorder

The Epilepsy Foundation of Minnesota is partnering with Mayo Clinic to host a regional patient education conference called “Living with Seizures: Today & Tomorrow.” The regional conference will feature national experts in epilepsy, panel discussions and breakout sessions that include the following topics:

5 Oct 2009

comScore study results of changes in search engine marketing in the pharmaceutical industry

comScore, Inc., a leader in measuring the digital world, today released the results of a study of changes in search engine marketing in the pharmaceutical industry as a result of the FDA warning letters distributed in March 2009.

5 Oct 2009

Study identifies new genes associated with head and neck cancer

A Henry Ford Hospital study has identified 231 new genes associated with head and neck cancer, one of the most deadly cancers responsible for 2.1 percent of all cancer deaths in the United States.

5 Oct 2009

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration.

From CSL Ltd 5 Oct 2009

Workshop to revise and update Pharmacy Benefit Management and Drug Therapy Management

URAC, the nation's leading health care accreditation and education organization, will introduce new performance measures and reporting standards to its Pharmacy Benefit Management (PBM) and Drug Therapy Management (DTM) Accreditation programs at a workshop focused on the latest revisions and updates to the standards.

5 Oct 2009

Researchers engineer antidotes for blood-thinner aptamers

Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately - because the blood thinner and antidote were designed to work together. Researchers at Duke University Medical Center have engineered a way to do this for an entire, versatile class of drugs called aptamers and published their findings in Nature Medicine.

4 Oct 2009

The EURORDIS and NORD rare disease organizations form a partnership

The leading advocacy groups for Americans and Europeans with rare diseases -- the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) -- have signed a Memorandum of Understanding to join forces on several key strategic initiatives on behalf of rare disease patients and their families.

3 Oct 2009

Retinoic acid may provide relief for ulcerative colitis

Here's another reason why you should take your vitamins. A new research report appearing in the October 2009 print issue of the Journal of Leukocyte Biology (http://www.jleukbio.org) suggests that retinoic acid, the oxidized form of vitamin A, could be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases.

3 Oct 2009

Report on the worldwide market for anti-infectives

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

3 Oct 2009

Survey: Recession affects 53 percent women with their decision on facial plastic surgery

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) will announce the results of a survey conducted with Dermik Laboratories, a business of sanofi-aventis U.S. LLC, which found that 53 percent of women who are considering facial plastic surgery say the economy has affected their decision to move forward with anti-aging procedures or treatment options. As a result, slightly more than 30 percent of women considering facial plastic surgery in the near future have looked for less costly procedures or treatment alternatives. The survey will be presented today at the Academy's Annual Fall meeting and will be available on a live Web cast at www.aafprs.org.

3 Oct 2009

CSPI sues Bayer for false claims on Men's One A Day multivitamins

The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.

3 Oct 2009

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine.

3 Oct 2009

Bradycardia more likely in patients taking cholinesterase inhibitors

People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications.

3 Oct 2009

Electronic medical records: A valuable asset to healthcare industry

Hundreds of billions of gigabytes of health information are now being collected in electronic medical records, and three-quarters (76%) of more than 700 healthcare executives recently surveyed by PricewaterhouseCoopers LLP agree that the secondary use of this information will be their organization's greatest asset over the next five years.

3 Oct 2009

Study points to subtle differences between boys and girls' attitudes to multiple drugs

New research by Weill Cornell Medical College researchers looks at the specific ways parents and peers influence teenagers to smoke, drink and use marijuana in combination.

3 Oct 2009

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as Kip1, CDKN1B).

From Thermo Fisher Scientific Inc. 3 Oct 2009

Scientists identify measures for reducing $2 billion healthcare burden from substance abuse

With substance abuse now accounting for one in 14 hospital admissions and generating billions in health care costs, leading scientists held a briefing on Capitol Hill today to present the evidence that we already have and the evidence we need in treating and preventing the use and abuse of alcohol, drugs and tobacco.

3 Oct 2009

Drugs News and Research

Allergan files declaratory relief action to allow it to share relavant information on BOTOX

JCA-Mauvernay Award presented to Dr Toshikazu Ushijima for his research in oncology

CIGNA survey shows employees in small business look for ways to save money on medication

National experts to address epilepsy disorder

comScore study results of changes in search engine marketing in the pharmaceutical industry

Study identifies new genes associated with head and neck cancer

The Lewin Group issues recommendations to overcome barriers obstructing the lupus drug development

Workshop to revise and update Pharmacy Benefit Management and Drug Therapy Management

Researchers engineer antidotes for blood-thinner aptamers

The EURORDIS and NORD rare disease organizations form a partnership

Retinoic acid may provide relief for ulcerative colitis

Report on the worldwide market for anti-infectives

Survey: Recession affects 53 percent women with their decision on facial plastic surgery

CSPI sues Bayer for false claims on Men's One A Day multivitamins

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Bradycardia more likely in patients taking cholinesterase inhibitors

Electronic medical records: A valuable asset to healthcare industry

Study points to subtle differences between boys and girls' attitudes to multiple drugs

RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

Scientists identify measures for reducing $2 billion healthcare burden from substance abuse

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News